Explore terminated, suspended, and withdrawn clinical trials

Review of Cohort 1 data facilitated direct enrollment into open label study and eliminate pause in study drug administration between PK study and open label study.

recruitment difficulties

Revisions to eligibility/design being made prior to enrollment of first participants.

Administrative hold pending non-safety related changes to the study design.

The sponsor requested to terminate the study.

This decision is based on a strategic company decision to discontinue development of this program as part of our portfolio prioritization.

Administrative reasons.

Business Reasons

The study remains on hold due to a funding issue after it's been lifted by the FDA.

no participants enrolled

Study was not initiated because funding was not received.

Novartis terminated the trial early because the collected data were sufficient to perform the analysis stated for the primary endpoint.

Study REL-1017-302 was terminated early by the Sponsor following the prespecified interim analysis for sample size re-estimation at approximately 75% enrollment of the planned sample size (N=280). Safety data were collected.

data analysis unequivocal - requires study methodology re-evaluation

Plans to rejoin a center

IRB Approval Expiration

Study terminated due to early participant drop out

Study REL-1017-304 was terminated early by the Sponsor following the prespecified interim analysis for sample size re-estimation conducted in study REL-1017-302. Safety assessments were performed in both studies in accordance with the study protocols

The early termination of this study is justified by changes in the recommendations. Specifically, a paravertebral block-that is, a regional anesthesia technique-is now recommended. Consequently, subject recruitment has been halted.

Study halted prematurely, prior to enrollment of first participant

ASTX660-03 was closed according to protocol as no safe and tolerable dosing for the combination of tolinapant and decitabine/cedazuridine was identified based on protocol defined criteria.

Clinical Hold

This study was not conducted

BMS terminated the study

Business decision

Study suspended due to a new development; the project was no longer feasible.

The study is withdrawn due to strategic reasons.

The study is withdrawn due to strategic reasons.

Business reasons and not due to any safety concerns

Initial prep showed that formulation, QC, and cost for high-dose paeonol/Cortex Moutan exceeded the budget. Also, recruiting patients with chemotherapy-induced peripheral neuropathy was limited. To ensure safety, enrollment did not officially launch.

Business objectives have changed

Study termination based on sponsor decision due to lack of tolerability observed with \[177Lu\]Lu-EVS459

Sponsor Decision

SOC changed and low enrollment

The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not driven by any new or unexpected safety concerns.

opening up at a different site

Accrual was permanently closed due to futility in the experimental arm on June 22, 2023. Follow-up in the experimental arm was extended to 117 weeks.

Other - review of safety data

The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape.

New information received

Study on hold pending possible updates with the team.

Poor Enrollment

Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.

Other - safety run-in for initial cohort of participants

Other - Pending amendment.

The study was terminated because of insufficient funding to complete the planned research activities.

Product expired, new lots not available

Terminated due to limited anti-cancer activity

The study has not actually been conducted.

Intercept made a business decision to terminate the study based on FDA's request for voluntary withdrawal of Ocaliva and the issuance of clinical hold on studies under US IND involving OCA.